Version 1
: Received: 1 February 2018 / Approved: 5 February 2018 / Online: 5 February 2018 (03:10:08 CET)
How to cite:
Esfandiari, H.; Shazly, T.; Shah, P.; Hassanpour, K.; Torkian, P.; Yaseri, M.; Loewen, N.A. Impact of Same-Session Trabectome Surgery on Ahmed Glaucoma Valve Outcomes. Preprints2018, 2018020017. https://doi.org/10.20944/preprints201802.0017.v1
Esfandiari, H.; Shazly, T.; Shah, P.; Hassanpour, K.; Torkian, P.; Yaseri, M.; Loewen, N.A. Impact of Same-Session Trabectome Surgery on Ahmed Glaucoma Valve Outcomes. Preprints 2018, 2018020017. https://doi.org/10.20944/preprints201802.0017.v1
Esfandiari, H.; Shazly, T.; Shah, P.; Hassanpour, K.; Torkian, P.; Yaseri, M.; Loewen, N.A. Impact of Same-Session Trabectome Surgery on Ahmed Glaucoma Valve Outcomes. Preprints2018, 2018020017. https://doi.org/10.20944/preprints201802.0017.v1
APA Style
Esfandiari, H., Shazly, T., Shah, P., Hassanpour, K., Torkian, P., Yaseri, M., & Loewen, N.A. (2018). Impact of Same-Session Trabectome Surgery on Ahmed Glaucoma Valve Outcomes. Preprints. https://doi.org/10.20944/preprints201802.0017.v1
Chicago/Turabian Style
Esfandiari, H., Mehdi Yaseri and Nils A. Loewen. 2018 "Impact of Same-Session Trabectome Surgery on Ahmed Glaucoma Valve Outcomes" Preprints. https://doi.org/10.20944/preprints201802.0017.v1
Abstract
Purpose: To evaluate the efficacy and survival rates of same session ab interno trabeculectomy with the trabectome and Ahmed glaucoma valve implant (AT) in comparison to the Ahmed glaucoma valve alone (A). Method: A total of 107 eyes undergoing primary glaucoma surgery were enrolled in this retrospective comparative case series, including 48 eyes which underwent AT and 59 eyes which received A alone. Participants were identified using the procedural terminology codes, and their medical records were reviewed. The primary outcome measure was surgical success, defined as intraocular pressure (IOP) > 5 mmHg, ≤ 21 mmHg, and IOP reduction ≥ 20% from baseline at two consecutive visits after three months, no reoperation for glaucoma. Secondary outcome measures were IOP, the number of glaucoma medications, incidence of a hypertensive phase, and best corrected visual acuity (BCVA). Results: The cumulative probability of success at one year was 70% in AT, and 65% in A (p=0.85). IOP decreased significantly from 26.6 ± 10.1 mmHg at baseline to 14.7 ± 3.3 mmHg at the final follow-up in AT (p= 0.001). The corresponding numbers for A were 28.8 ± 10.2 and 16.7 ± 4.9, respectively (p= 0.001). The final IOP was significantly lower in AT (p= 0.022). The number of medications at baseline was comparable in both groups (2.6 ± 1.2 in AT and 2.5 ± 1.3 in A, p=0.851). Corresponding number at 1 year visit was 1.2±2 in AT and 2.8±1.8 in A (p=0.001). The incidence of a hypertensive phase was 18.7% in AT and 35.5% in A (p=0.05). HP resolved in only 30% of eyes. The criteria for HP resolution were fulfilled in 9 eyes (30%). There was no difference in the rate of resolution of the hypertensive phase between AT and A (33.3% and 28.5%, respectively, p=0.67). Conclusion: Ahmed glaucoma valve implant with same session trabectome surgery significantly decreased the rate of the hypertensive phase and postoperative IOP as well as the number of glaucoma medications.
Keywords
Ahmed glaucoma valve; trabectome surgery; hypertensive phase; glaucoma surgery
Subject
Medicine and Pharmacology, Ophthalmology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
